Nowoczesne leczenie przeciwzakrzepowe u pacjentów z chorobami miażdżycowymi. Miejsce rywaroksabanu w aktualnych wytycznych oraz codziennej praktyce klinicznej Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2024
Słowa kluczowe:
rywaroksaban, leczenie przeciwzakrzepowe, choroby sercowo-naczyniowe na podłożu miażdżycy
##plugins.themes.bootstrap3.article.main##
Abstrakt
Choroba układu sercowo-naczyniowego na podłożu miażdżycy (ASCVD, atherosclerotic cardiovascular disease), która obejmuje chorobę wieńcową, chorobę naczyń mózgowych oraz chorobę tętnic obwodowych, wiąże się z wysoką zachorowalnością, śmiertelnością i kosztochłonnością w aspekcie populacyjnym. Monoterapia przeciwpłytkowa była od dawna podstawą leczenia przeciwzakrzepowego w profilaktyce pierwotnej i wtórnej incydentów w ASCVD. Ostatnie randomizowane badania pokazały zalety i efektywność strategii dwukierunkowego hamowania w przewlekłej ASCVD. Kwas acetylosalicylowy i mała dawka rywaroksabanu zastosowane w skojarzeniu działają synergistycznie i stanowią atrakcyjną opcję terapeutyczną u wybranych grup pacjentów.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Stępień, K., & Gajos, G. (2024). Nowoczesne leczenie przeciwzakrzepowe u pacjentów z chorobami miażdżycowymi. Miejsce rywaroksabanu w aktualnych wytycznych oraz codziennej praktyce klinicznej . Medycyna Faktów , 17(1(62), 43-50. https://doi.org/10.24292/01.MF.0124.07
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Roth GA, Mensah GA, Johnson CO et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020; 76: 2982-3021.
2. Bhatt DL, Steg PG, Ohman EM et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006; 295: 180-9.
3. Stepien K, Nowak K, Skorek P et al. Baseline indicators of coronary artery disease burden in patients with non-ST-segment elevation acute coronary syndrome. Minerva Cardioangiol. 2019; 67: 181-90.
4. Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual\ participant data from randomised trials. Lancet. 2009; 373: 1849-60.
5. Byrne RA, Rossello X, Coughlan JJ et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023; 44: 3720-826.
6. Kleindorfer DO, Towfighi A, Chaturvedi S et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021; 52: e364-467.
7. Gerhard-Herman MD, Gornik HL, Barrett C et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017; 135: e686-725.
8. Bhatt DL, Fox KAA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354: 1706-17.
9. Bonaca MP, Bhatt DL, Cohen M et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372: 1791-800.
10. Udell JA, Bonaca MP, Collet JP et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016; 37: 390-9.
11. Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019; 381: 1309-20.
12. Diener HC, Bogousslavsky J, Brass L et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004; 364: 331-7.
13. Zalewski J, Stepien K, Nowak K et al. Delayed Thrombin Generation Is Associated with Minor Bleedings in Venous Thromboembolism Patients on Rivaroxaban: Usefulness of Calibrated Automated Thrombography. J Clin Med. 2020; 9: 2018.
14. Andreotti F, Testa L, Biondi-Zoccai GGL et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006; 27: 519-26.
15. Anand S, Yusuf S, Xie C et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007; 357: 217-27.
16. Alexander JH, Lopes RD, James S et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011; 365: 699-708.
17. Mega JL, Braunwald E, Mohanavelu S et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009; 374: 29-38.
18. Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366: 9-19.
19. Eikelboom J, Connolly S, Bosch J et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017; 377: 1319-30.
20. Bonaca MP, Bauersachs RM, Hiatt WR et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020; 382: 1994-2004.
2. Bhatt DL, Steg PG, Ohman EM et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006; 295: 180-9.
3. Stepien K, Nowak K, Skorek P et al. Baseline indicators of coronary artery disease burden in patients with non-ST-segment elevation acute coronary syndrome. Minerva Cardioangiol. 2019; 67: 181-90.
4. Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual\ participant data from randomised trials. Lancet. 2009; 373: 1849-60.
5. Byrne RA, Rossello X, Coughlan JJ et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023; 44: 3720-826.
6. Kleindorfer DO, Towfighi A, Chaturvedi S et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021; 52: e364-467.
7. Gerhard-Herman MD, Gornik HL, Barrett C et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017; 135: e686-725.
8. Bhatt DL, Fox KAA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354: 1706-17.
9. Bonaca MP, Bhatt DL, Cohen M et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372: 1791-800.
10. Udell JA, Bonaca MP, Collet JP et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016; 37: 390-9.
11. Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019; 381: 1309-20.
12. Diener HC, Bogousslavsky J, Brass L et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004; 364: 331-7.
13. Zalewski J, Stepien K, Nowak K et al. Delayed Thrombin Generation Is Associated with Minor Bleedings in Venous Thromboembolism Patients on Rivaroxaban: Usefulness of Calibrated Automated Thrombography. J Clin Med. 2020; 9: 2018.
14. Andreotti F, Testa L, Biondi-Zoccai GGL et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006; 27: 519-26.
15. Anand S, Yusuf S, Xie C et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007; 357: 217-27.
16. Alexander JH, Lopes RD, James S et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011; 365: 699-708.
17. Mega JL, Braunwald E, Mohanavelu S et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009; 374: 29-38.
18. Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366: 9-19.
19. Eikelboom J, Connolly S, Bosch J et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017; 377: 1319-30.
20. Bonaca MP, Bauersachs RM, Hiatt WR et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020; 382: 1994-2004.